1AD Stock Overview
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AdAlta Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.027 |
| 52 Week High | AU$0.048 |
| 52 Week Low | AU$0.017 |
| Beta | 0.72 |
| 1 Month Change | 12.50% |
| 3 Month Change | 12.50% |
| 1 Year Change | 0% |
| 3 Year Change | -82.00% |
| 5 Year Change | -85.79% |
| Change since IPO | -90.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1AD | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -6.9% | -2.1% | -2.8% |
| 1Y | 0% | -8.1% | 4.0% |
Return vs Industry: 1AD exceeded the Australian Biotechs industry which returned -8.1% over the past year.
Return vs Market: 1AD underperformed the Australian Market which returned 4% over the past year.
Price Volatility
| 1AD volatility | |
|---|---|
| 1AD Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: 1AD's share price has been volatile over the past 3 months.
Volatility Over Time: 1AD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 10 | Tim Oldham | www.adalta.com.au |
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens.
AdAlta Limited Fundamentals Summary
| 1AD fundamental statistics | |
|---|---|
| Market cap | AU$14.20m |
| Earnings (TTM) | -AU$5.04m |
| Revenue (TTM) | AU$3.50m |
4.1x
P/S Ratio-2.8x
P/E RatioIs 1AD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AD income statement (TTM) | |
|---|---|
| Revenue | AU$3.50m |
| Cost of Revenue | AU$235.86k |
| Gross Profit | AU$3.26m |
| Other Expenses | AU$8.31m |
| Earnings | -AU$5.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0096 |
| Gross Margin | 93.26% |
| Net Profit Margin | -144.13% |
| Debt/Equity Ratio | 82.9% |
How did 1AD perform over the long term?
See historical performance and comparison